BCLI - BrainStorm shares surge 20% on positive NurOwn data in multiple sclerosis

BrainStorm Cell Therapeutics (BCLI) soars 20% premarket after announcing topline data from Phase 2 trial evaluating three repeated administrations of NurOwn (MSC-NTF cells), each given 2 months apart, as a treatment for progressive multiple sclerosis ((MS)).The study achieved the primary endpoint of safety and improvements were observed in secondary endpoints spanning neurologic function, cognition, and biomarkers.Of the 20 patients enrolled, 18 were treated and 16 (80%) completed the study. Two patients discontinued due to adverse events (AEs).Prespecified 25% improvements in the timed 25-foot walk (T25FW) and 9-hole peg test (9-HPT) from baseline to 28 weeks were observed in 14% and 13% of NurOwn treated patients, respectively, and was observed in 0% of the pre-specified matched historical controls in the CLIMB registry.NurOwn treated patients showed a mean improvement of 10% in T25FW and a 4.8% improvement on the 9-HPT dominant hand, compared to 1.8% and 1.4% worsening respectively in matched historical controls from

For further details see:

BrainStorm shares surge 20% on positive NurOwn data in multiple sclerosis